Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Astrazeneca (AZN) Share News

UK earnings, trading statements calendar - next 7 days

23rd Oct 2026 13:57

Read More

Daiichi Sankyo wins China Enhertu approval; reports cancer study data

23rd Oct 2026 13:16

(Alliance News) - Daiichi Sankyo Co Ltd on Friday said its cancer treatment Enhertu has received regulatory approval in China, while the company announced "promising" trial results. Read More

WINNERS & LOSERS: Luxury sector woes hurt Burberry; oil majors climb

23rd Oct 2026 10:49

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday. Read More

AstraZeneca's Alexion wins accelerated US approval for kidney drug

22nd Oct 2026 10:24

(Alliance News) - AstraZeneca PLC on Thursday said subsidiary Alexion Pharmaceutical's Ultomiris has received accelerated approval in the US for the treatment of a rare kidney disease called immunoglobulin A nephropathy. Read More

IN BRIEF: AstraZeneca wins US approval for Ultomiris in kidney disease

22nd Oct 2026 09:45

AstraZeneca PLC - Cambridge, England-based pharmaceutical company - Says its Ultomiris drug has received accelerated approval from the US Food & Drug Administration to reduce proteinuria, or excess protein in urine, in adults with primary immunoglobulin A nephropathy, a rare inflammatory kidney disease, who are at risk of disease progression. Ultomiris becomes the first and only C5 complement inhibitor approved in the US for this indication. Approval follows interim results from the phase III I CAN trial, which showed a 43.4% reduction in proteinuria compared with placebo after 34 weeks. AstraZeneca says the trial remains ongoing to assess whether Ultomiris can slow kidney function decline, with continued approval potentially dependent on confirmation of clinical benefit. The approval marks the fifth indication for Ultomiris. Read More

Amgen and AstraZeneca celebrate positive Tezspire trial results in EoE

20th Oct 2026 15:00

(Alliance News) - Amgen Inc and AstraZeneca PLC on Tuesday hailed phase 3 trial results regarding their monoclonal antibody Tezspire, also known as tezepelumab. Read More

AstraZeneca and Oracle partner to advance AI in clinical trials

20th Oct 2026 11:34

(Alliance News) - AstraZeneca PLC and Oracle Corp on Tuesday announced a global collaboration to use artificial intelligence to improve clinical trials, patient diagnosis and treatment. Read More

WINNERS & LOSERS: Genuit falls on profit warning; Bunzl growth cools

20th Oct 2026 10:26

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. Read More

LONDON MARKET CLOSE: FTSE forges ahead but banks stutter on tax threat

16th Oct 2026 17:02

(Alliance News) - The FTSE 100 made further strong gains on Friday as Bank of England Governor Andrew Bailey played down inflation fears, although banks missed out amid fears of a tax hit. Read More

PRESS: UK government courted UBS over potential London move - FT

16th Oct 2026 13:33

(Alliance News) - The UK government has sought to persuade UBS Group AG to relocate its headquarters and stock market listing to London, as the Swiss banking giant considers its options amid tougher capital requirements in Switzerland, the Financial Times reported on Friday. Read More

WINNERS & LOSERS: Banks fall on tax worry; Man Group assets up

16th Oct 2026 10:05

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Friday. Read More

AstraZeneca announces AI system collaboration with insitro

15th Oct 2026 12:11

(Alliance News) - AstraZeneca PLC on Thursday announced its entry into a strategic drug discovery collaboration and licensing agreement with insitro. Read More

LONDON MARKET CLOSE: FTSE 100 closes higher despite hot US inflation

14th Oct 2026 17:22

(Alliance News) - The FTSE 100 ended higher on Wednesday, despite strong US inflation data, as the Bank of England's chief economist played down fears of multiple interest rate rises in the UK. Read More

LONDON MARKET CLOSE: FTSE 100 closes higher despite hot US inflation

14th Oct 2026 17:09

(Alliance News) - The FTSE 100 ended higher on Wednesday, despite strong US inflation data, as the Bank of England's chief economist played down fears of multiple interest rate rises in the UK. Read More

WINNERS & LOSERS: BP climbs as trims net debt; tech investors struggle

13th Oct 2026 09:42

(Alliance News) - The following are the leading risers and fallers among FTSE 100 and 250 index constituents on Tuesday. Read More

AstraZeneca HPP trial results miss statistical significance

12th Oct 2026 01:54

(Alliance News) - AstraZeneca PLC on Sunday said results from its phase three trial of Efzimfotase alfa showed improvement but failed to achieve statistical significance. Read More

AstraZeneca, Daiichi cancer drugs approved in China for new uses

8th Oct 2026 11:23

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Thursday said the drugs Enhertu and Datroway received new approvals for breast cancer treatment applications in China. Read More

LONDON BROKER RATINGS: Deutsche Bank ups Glencore, BHP price targets

7th Oct 2026 09:05

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday: Read More

AztraZeneca opens new global strategic R&D centre in Massachusetts

5th Oct 2026 19:28

(Alliance News) - AstraZeneca PLC on Monday announced the opening of its newest global strategic research and development centre, in Massachusetts. Read More

IN BRIEF: AstraZeneca completes USD2 billion Summit investment

5th Oct 2026 12:53

AstraZeneca PLC - Cambridge, England-based pharmaceutical company - Says it has successfully completed its USD2 billion equity investment in Summit Therapeutics. The funding will accelerate the development of first-in-class bispecific antibody ivonescimab, which targets PD-1 and VEGF across multiple tumour types in combination with antibody-drug conjugates. Notes that it has also entered a clinical collaboration agreement with Summit to evaluate sonesitatug vedotin in combination with ivonescimab. They also intend to enter an additional deal, which would initiate a global development programme combining other AstraZeneca cancer medicines. Read More

FTSE 100 Latest
Value10,506.58
Change-44.59